Concepts (144)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Angioedema | 2 | 2018 | 111 | 0.79 | Why? |
| Omalizumab | 2 | 2018 | 158 | 0.77 | Why? |
| Hypereosinophilic Syndrome | 1 | 2018 | 33 | 0.72 | Why? |
| Interleukin-10 | 2 | 2017 | 1409 | 0.68 | Why? |
| Immunologic Deficiency Syndromes | 2 | 2018 | 368 | 0.66 | Why? |
| Infliximab | 2 | 2018 | 502 | 0.62 | Why? |
| Clinical Deterioration | 1 | 2020 | 473 | 0.60 | Why? |
| Biological Products | 2 | 2020 | 2331 | 0.59 | Why? |
| Hypersensitivity | 2 | 2020 | 1137 | 0.49 | Why? |
| Antigens | 1 | 2014 | 267 | 0.48 | Why? |
| Immunoglobulin E | 4 | 2018 | 557 | 0.46 | Why? |
| Asthma | 6 | 2020 | 4383 | 0.45 | Why? |
| Biological Factors | 1 | 2014 | 276 | 0.43 | Why? |
| Immune System Diseases | 3 | 2019 | 410 | 0.39 | Why? |
| Adenine | 1 | 2011 | 463 | 0.35 | Why? |
| Antibodies | 1 | 2014 | 846 | 0.35 | Why? |
| Toll-Like Receptor 7 | 1 | 2011 | 402 | 0.33 | Why? |
| Interleukin-17 | 1 | 2011 | 602 | 0.31 | Why? |
| Interleukin-6 | 2 | 2020 | 7522 | 0.29 | Why? |
| Anti-Asthmatic Agents | 2 | 2018 | 427 | 0.25 | Why? |
| Dendritic Cells | 3 | 2018 | 1330 | 0.25 | Why? |
| T-Lymphocytes | 2 | 2017 | 6670 | 0.23 | Why? |
| Fever | 1 | 2018 | 7795 | 0.22 | Why? |
| Inflammation | 2 | 2020 | 13255 | 0.21 | Why? |
| Antibodies, Monoclonal, Humanized | 2 | 2018 | 9335 | 0.19 | Why? |
| Haemophilus Infections | 1 | 2019 | 69 | 0.19 | Why? |
| Cytotoxicity, Immunologic | 1 | 2020 | 287 | 0.18 | Why? |
| Haemophilus influenzae | 1 | 2019 | 196 | 0.18 | Why? |
| Interleukin-5 | 1 | 2018 | 138 | 0.18 | Why? |
| Basophils | 1 | 2018 | 179 | 0.18 | Why? |
| Academies and Institutes | 1 | 2020 | 539 | 0.16 | Why? |
| Coculture Techniques | 1 | 2017 | 258 | 0.16 | Why? |
| Agammaglobulinemia | 1 | 2018 | 213 | 0.15 | Why? |
| Pneumonia, Pneumococcal | 1 | 2019 | 251 | 0.15 | Why? |
| Common Variable Immunodeficiency | 1 | 2018 | 195 | 0.15 | Why? |
| Genetic Diseases, X-Linked | 1 | 2018 | 237 | 0.15 | Why? |
| Giant Cell Arteritis | 1 | 2018 | 137 | 0.15 | Why? |
| Radioimmunoassay | 1 | 2014 | 25 | 0.15 | Why? |
| Eosinophilia | 1 | 2018 | 292 | 0.14 | Why? |
| T-Lymphocytes, Helper-Inducer | 1 | 2018 | 497 | 0.14 | Why? |
| Leukocytes, Mononuclear | 2 | 2017 | 2115 | 0.14 | Why? |
| Cytokines | 3 | 2020 | 15010 | 0.14 | Why? |
| Remission Induction | 1 | 2018 | 950 | 0.14 | Why? |
| Immunotherapy | 2 | 2019 | 2421 | 0.14 | Why? |
| Immunoglobulin G | 1 | 2018 | 21571 | 0.13 | Why? |
| Streptococcus pneumoniae | 1 | 2019 | 827 | 0.13 | Why? |
| B-Lymphocytes | 3 | 2020 | 4418 | 0.13 | Why? |
| Immunoglobulins | 1 | 2018 | 811 | 0.12 | Why? |
| Surface Plasmon Resonance | 1 | 2014 | 440 | 0.12 | Why? |
| Drug Hypersensitivity | 1 | 2018 | 401 | 0.11 | Why? |
| Anaphylaxis | 1 | 2021 | 940 | 0.11 | Why? |
| Injections, Intraperitoneal | 1 | 2011 | 69 | 0.11 | Why? |
| Galactosylceramides | 1 | 2011 | 22 | 0.11 | Why? |
| Eosinophils | 1 | 2018 | 848 | 0.11 | Why? |
| Rituximab | 1 | 2019 | 1096 | 0.11 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.11 | Why? |
| Electrochemical Techniques | 1 | 2014 | 406 | 0.10 | Why? |
| Kaplan-Meier Estimate | 1 | 2020 | 4260 | 0.10 | Why? |
| Adult | 13 | 2020 | 244371 | 0.10 | Why? |
| Interleukin-13 | 1 | 2011 | 204 | 0.10 | Why? |
| Male | 15 | 2021 | 367725 | 0.09 | Why? |
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2017 | 645 | 0.09 | Why? |
| Leukocyte Count | 1 | 2018 | 3178 | 0.09 | Why? |
| ROC Curve | 1 | 2020 | 6024 | 0.09 | Why? |
| Cost of Illness | 1 | 2018 | 1903 | 0.09 | Why? |
| Lymphocyte Activation | 1 | 2017 | 2742 | 0.08 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2014 | 7868 | 0.08 | Why? |
| Th2 Cells | 1 | 2011 | 680 | 0.08 | Why? |
| Female | 14 | 2020 | 380317 | 0.08 | Why? |
| Clinical Protocols | 1 | 2018 | 2734 | 0.08 | Why? |
| Young Adult | 6 | 2020 | 93724 | 0.08 | Why? |
| Oxygen | 1 | 2020 | 3715 | 0.08 | Why? |
| Middle Aged | 12 | 2020 | 270681 | 0.08 | Why? |
| Th17 Cells | 1 | 2011 | 657 | 0.07 | Why? |
| Patient Satisfaction | 1 | 2018 | 2517 | 0.07 | Why? |
| Humans | 21 | 2021 | 930598 | 0.07 | Why? |
| Immunologic Memory | 1 | 2017 | 3362 | 0.07 | Why? |
| Cells, Cultured | 2 | 2018 | 5835 | 0.07 | Why? |
| Immunoglobulins, Intravenous | 1 | 2017 | 2705 | 0.07 | Why? |
| Aged | 9 | 2021 | 215776 | 0.07 | Why? |
| Azithromycin | 1 | 2019 | 3943 | 0.07 | Why? |
| Europe | 1 | 2020 | 12702 | 0.06 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.06 | Why? |
| Antirheumatic Agents | 1 | 2018 | 3023 | 0.06 | Why? |
| Treatment Outcome | 6 | 2019 | 51732 | 0.06 | Why? |
| Follow-Up Studies | 2 | 2018 | 17020 | 0.06 | Why? |
| Length of Stay | 1 | 2020 | 11042 | 0.06 | Why? |
| Severity of Illness Index | 3 | 2020 | 48226 | 0.06 | Why? |
| Interferon-gamma | 1 | 2011 | 2711 | 0.05 | Why? |
| Immunoglobulin M | 1 | 2018 | 9091 | 0.05 | Why? |
| Receptors, Virus | 1 | 2017 | 5659 | 0.05 | Why? |
| Gene Expression | 1 | 2011 | 3332 | 0.05 | Why? |
| Granzymes | 1 | 2020 | 197 | 0.05 | Why? |
| Mice, Inbred C57BL | 1 | 2011 | 5542 | 0.05 | Why? |
| Receptors, IgE | 1 | 2018 | 26 | 0.05 | Why? |
| Antigens, CD20 | 1 | 2019 | 105 | 0.05 | Why? |
| Epinephrine | 1 | 2021 | 323 | 0.05 | Why? |
| Antibodies, Monoclonal | 1 | 2018 | 8041 | 0.05 | Why? |
| CD40 Ligand | 1 | 2018 | 121 | 0.05 | Why? |
| Lymphocyte Depletion | 1 | 2019 | 293 | 0.04 | Why? |
| Cohort Studies | 2 | 2018 | 36005 | 0.04 | Why? |
| Biomarkers | 1 | 2020 | 23361 | 0.04 | Why? |
| Time Factors | 1 | 2020 | 31397 | 0.04 | Why? |
| Injections, Subcutaneous | 1 | 2018 | 647 | 0.04 | Why? |
| Monte Carlo Method | 1 | 2018 | 577 | 0.04 | Why? |
| Comorbidity | 1 | 2020 | 34796 | 0.04 | Why? |
| Aged, 80 and over | 3 | 2020 | 88759 | 0.04 | Why? |
| Models, Immunological | 1 | 2020 | 727 | 0.04 | Why? |
| Pneumonia, Viral | 2 | 2020 | 243684 | 0.04 | Why? |
| Coronavirus Infections | 2 | 2020 | 253789 | 0.03 | Why? |
| Administration, Intravenous | 1 | 2018 | 1115 | 0.03 | Why? |
| Retrospective Studies | 3 | 2020 | 105322 | 0.03 | Why? |
| Surveys and Questionnaires | 1 | 2020 | 43792 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.03 | Why? |
| Positron-Emission Tomography | 1 | 2018 | 802 | 0.03 | Why? |
| Italy | 3 | 2021 | 38444 | 0.03 | Why? |
| Mice | 1 | 2011 | 21357 | 0.03 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 13720 | 0.03 | Why? |
| Killer Cells, Natural | 1 | 2020 | 2093 | 0.03 | Why? |
| Animals | 3 | 2019 | 78931 | 0.03 | Why? |
| Fluorodeoxyglucose F18 | 1 | 2018 | 1153 | 0.03 | Why? |
| Drug Monitoring | 1 | 2018 | 1408 | 0.03 | Why? |
| Dose-Response Relationship, Drug | 1 | 2019 | 3776 | 0.02 | Why? |
| Double-Blind Method | 1 | 2019 | 5988 | 0.02 | Why? |
| Prevalence | 2 | 2020 | 25773 | 0.02 | Why? |
| Critical Care | 2 | 2020 | 14081 | 0.02 | Why? |
| Patient Compliance | 1 | 2017 | 1468 | 0.02 | Why? |
| Inflammation Mediators | 1 | 2018 | 2654 | 0.02 | Why? |
| Betacoronavirus | 2 | 2020 | 204454 | 0.02 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2020 | 4545 | 0.02 | Why? |
| Pandemics | 3 | 2020 | 389249 | 0.02 | Why? |
| CD8-Positive T-Lymphocytes | 1 | 2020 | 5837 | 0.02 | Why? |
| Immunity, Humoral | 1 | 2018 | 4849 | 0.02 | Why? |
| Lung | 1 | 2011 | 31049 | 0.01 | Why? |
| Glucocorticoids | 1 | 2018 | 4431 | 0.01 | Why? |
| Disease Progression | 1 | 2019 | 13580 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2018 | 10649 | 0.01 | Why? |
| Incidence | 1 | 2021 | 25622 | 0.01 | Why? |
| Adolescent | 2 | 2018 | 86841 | 0.01 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.01 | Why? |
| Respiration, Artificial | 1 | 2020 | 22116 | 0.01 | Why? |
| Prognosis | 1 | 2018 | 32490 | 0.01 | Why? |
| Prospective Studies | 1 | 2017 | 43301 | 0.01 | Why? |
| Hospitalization | 1 | 2020 | 54280 | 0.01 | Why? |
Vultaggio's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts
(144)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(343)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_